QSAM Biosciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Austin, tx, april 16, 2024 (globe newswire) -- qsam biosciences, inc. (otcqb: qsam) (“qsam” or the “company”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of qsam's common stock, par value $0.0001 per share (“common stock”), at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company and telix pharmaceuticals limited (asx: tlx) (“telix”) pursuant to which telix will acquire qsam (the “merger”).

Melbourne, australia, feb. 08, 2024 (globe newswire) -- telix pharmaceuticals limited (asx: tlx, telix, the company) today announces it has entered into an agreement to acquire qsam biosciences, inc. (u.s. otc: qsam) and its lead investigational drug samarium-153-dotmp (153sm-dotmp). qsam is a united states (u.s.) based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

Austin, tx, feb. 07, 2024 (globe newswire) -- qsam biosciences inc. (otcqb: qsam) (“qsam or the “company”) has signed a definitive agreement and plan of merger (the “agreement”) providing for the acquisition of the company by telix pharmaceuticals limited (asx: tlx) (“telix”).

Austin, tx, nov. 14, 2023 (globe newswire) -- qsam biosciences inc. (otcqb: qsam), a company developing therapeutic radiopharmaceuticals for the treatment of primary and secondary bone cancer and related conditions, has signed a non-binding term sheet (the “term sheet”) with telix pharmaceuticals (us) inc., a subsidiary of telix pharmaceuticals limited (asx: tlx) (collectively, “telix”) providing material terms for the acquisition of the company by telix by means of a merger (the “acquisition”). upon signing of the term sheet, telix has agreed to pay the company a us$2 million pre-closing collaboration and option fee (the “collaboration fee”) to advance the company's development efforts based on mutually agreed goals and to provide sixty days of exclusivity pending completion of diligence and execution of a definitive acquisition agreement.

Melbourne, australia , nov. 13, 2023 /prnewswire/ -- telix pharmaceuticals limited (asx: tlx, telix, the company) today announces it has signed a conditional term sheet to acquire qsam biosciences, inc. (qsam) and its lead asset, cyclosam® (samarium-153-dotmp). qsam is a united states (u.s.) based clinical stage company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

QSAM invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.

Austin, TX, Aug. 25, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153 DOTMP (CycloSam®), for the treatment of cancer and related diseases and conditions, announced that the U.S. Food and Drug Administration (FDA) has cleared QSAM's investigational new drug (IND) application which allows the Company to commence Phase 1 clinical trials and the dosing of patients with bone cancer.

Palm Beach, FL, Aug. 11, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation nuclear medicines, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases and conditions, announced that the countries of Japan and Canada have granted patents covering “high purity therapeutic bone agents” in connection with the Company's CycloSam technology. The United States Patent & Trademark Office (USPTO) issued a patent on this innovation last year.

Austin, TX, April 19, 2021 (GLOBE NEWSWIRE) -- The Chief Executive Officer of Q SAM Biosciences Inc. (OTCQB: QSAM), Douglas Baum, provided the following letter to shareholders today:

Austin, Texas, March 17, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) announced today that it has signed an Exclusive Option Agreement with IsoTherapeutics Group, LLC to allow the Company a 120-day period to perform diligence and negotiate a worldwide, exclusive license agreement for a pre-clinical staged radiochemical therapy called BetaBrach™.

Austin, Texas;, Feb. 11, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM” or the “Company”), today announced that it became aware on February 9, 2021 of certain promotional activities concerning its common stock through notification by Issuer Services at OTC Markets Group (“OTC Markets”), including three electronic newsletters prepared by third parties – Market Caliber, OTC Tip Reporter, and StockOnions.com (the “Newsletters”). The Company was not aware of the Newsletters before receiving copies of the Newsletters from OTC Markets.